Biogen to cease production of controversial Alzheimer's drug

Key Facts

• | Steven Senne/AP Drugmaker Biogen will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment that also provoked controversy over conflicting data around its efficacy, the company said Wednesday.
• But after an internal review of its research and development efforts, the company determined that it should redirect its resources toward developing other drug candidates and advancing Leqembi, another Alzheimer’s drug it’s marketing with Eisai that won traditional FDA approval last year.
• “When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Christopher A. Viehbacher, Biogen’s president and CEO, said in a statement.
• “ADUHELM was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Click To Read Full Article